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Abstract
An abundantly growing body of literature implicates conjugation of SUMO in the regulation of many
proteins and processes, yet the regulation of SUMO pathways is poorly understood. To gain insight
into the players in the SUMO1 pathway I have performed an in-silico co-expression meta-analysis
of SUMO1, comparing many different multi-microarray studies of various normal and human
tumour tissues, from the Oncomine database. This serves as a data-driven predictor of pathway
partners of SUMO1. While the data obtained need to be confirmed by future independent
experiments and can currently only be considered a hypothesis, results implicate defender against
cell death (DAD1) and the anti-apoptotic DEK oncogene as new pathway partners of SUMO1.
Discussion
Oncomine [1] meta-analysis was performed as previously
described [2,3]. Briefly, 15 multi-array studies were ana-
lyzed for common overlapping co-expressed genes of
SUMO1, using muti-array studies within the Oncomine
integrated cancer database. This technique gives insight
into which pathways the searched gene (in this case
SUMO1) are involved in, although it is impossible to tell
if co-expressed gene products are complexed to SUMO1,
act upstream of SUMO1 or downstream of SUMO1.
Therefore, while limited, this technique is important for
generating leads to assess both the pathways SUMO1 is
important for, and regulation of SUMO1 itself.
After meta-analysis there were over 400 consistently co-
expressed genes at the cutoff of 3 studies (Additional File
1). Table 1 shows the genes with the higher cutoff of 4
studies. This high number may be expected as SUMO1 is
a general factor and involved in many processes. I note
that the archetype SUMO1-modified promyelocytic
leukemia (PML) was co-expressed with SUMO1, acting as
validation of the results [4]. While the Ubc9 conjugation
enzyme was not found to be co-expressed many other
ubiquitin-conjugating enzymes were (UBE2N,  UBE4A,
UBE2G1,  UBE2V2,  UBE2E1,  UBE2D2,  UBE2A,  UBE1C,
CUL4A), as was the SUMO1 activating enzyme subunit 2
(UBA2). Transcription factors shown to be modified by
SUMO were also co-expressed, such as HIF1α, Rb, YY1,
and SMAD4 [5-9]. Interestingly RARα is also co-expressed
and while it has never been shown to be a target of
SUMO1 the PML-RARα fusion has been shown to be a tar-
get of SUMO1 mediated degradation [10]. It would be
interesting to investigate if RARα itself is a SUMO1 target.
Also co-expressed is the NF-κB subunit RelA. While RelA
also is not a proven target of SUMO1 NF-κB is regulated
indirectly by SUMO1 modification of Iκ Kgamma/NEMO
or IκB [11,12].
A similar meta-analysis was attempted for SUMO2 and
SUMO3. However, SUMO2 was not expressed to levels
that allowed for meta-analysis, and the results of SUMO3
meta-analysis gave fewer co-expressed genes than for
SUMO1 (Additional File 2). There was a small overlap (37
genes) of co-expressed genes of SUMO1:SUMO3, but this
does not necessarily imply that both are involved in com-
pletely distinct pathways. Rather, the meta-analysis tech-
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Table 1: Oncomine meta-analysis of SUMO1 co-expressed genes
GENE % GENE NAME
SUMO1 100% SMT3 suppressor of mif two 3 homolog 1 (S. cerevisiae)
DAD1 67% defender against cell death 1
DEK 53% DEK oncogene (DNA binding)
UBE2N 47% ubiquitin-conjugating enzyme E2N (UBC13 homolog, yeast)
SET 47% SET translocation (myeloid leukemia-associated)
SLC25A5 40% solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5
SFRS3 40% splicing factor, arginine/serine-rich 3
RPA1 40% replication protein A1, 70 kDa
RCN2 40% Reticulocalbin 2, EF-hand calcium binding domain
RB1 40% retinoblastoma 1 (including osteosarcoma)
PSMD14 40% proteasome (prosome, macropain) 26S subunit, non-ATPase, 14
PSMC2 40% proteasome (prosome, macropain) 26S subunit, ATPase, 2
PSMA2 40% proteasome (prosome, macropain) subunit, alpha type, 2
NUP153 40% nucleoporin 153 kDa
GLO1 40% glyoxalase I
DPM1 40% dolichyl-phosphate mannosyltransferase polypeptide 1, catalytic subunit
DARS 40% Aspartyl-tRNA synthetase
CD164 40% CD164 antigen, sialomucin
CCT8 40% chaperonin containing TCP1, subunit 8 (theta)
BNIP2 40% BCL2/adenovirus E1B 19 kDa interacting protein 2
YY1 33% YY1 transcription factor
VPS16 33% vacuolar protein sorting 16 (yeast)
USP1 33% ubiquitin specific protease 1
UBE4A 33% ubiquitination factor E4A (homologous to yeast UFD2)
UBE2G1 33% ubiquitin-conjugating enzyme E2G 1 (UBC7 homolog, C. elegans)
TSNAX 33% translin-associated factor X
SSBP1 33% single-stranded DNA-binding protein 1
SMAD4 33% SMAD, mothers against DPP homolog 4 (Drosophila)
SIAHBP1 33% siah binding protein 1
SEC61B 33% Sec61 beta subunit
RIF1 33% RAP1 interacting factor homolog (yeast)
RBMX 33% RNA binding motif protein, X-linked
PSMA3 33% proteasome (prosome, macropain) subunit, alpha type, 3
PPP6C 33% protein phosphatase 6, catalytic subunit
POLD2 33% polymerase (DNA directed), delta 2, regulatory subunit 50 kDa
NCBP2 33% nuclear cap binding protein subunit 2, 20 kDa
IRS1 33% insulin receptor substrate 1
ILF3 33% interleukin enhancer binding factor 3, 90 kDa
HMGN4 33% high mobility group nucleosomal binding domain 4
H2AFV 33% H2A histone family, member V
G22P1 33% thyroid autoantigen 70 kDa (Ku antigen)
EIF2S3 33% eukaryotic translation initiation factor 2, subunit 3 gamma, 52 kDa
CUL1 33% cullin 1
C10orf7 33% chromosome 10 open reading frame 7
BZW1 33% basic leucine zipper and W2 domains 1
BRD2 33% bromodomain-containing 2
ATP6V0B 33% ATPase, H+ transporting, lysosomal 21 kDa, V0 subunit c'
ATP5J 33% ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F6
WEE1 27% WEE1 homolog (S. pombe)
VBP1 27% von Hippel-Lindau binding protein 1 (prefoldin 3)
UQCRC1 27% ubiquinol-cytochrome c reductase core protein I
UBXD2 27% UBX domain containing 2
TSN 27% translin
TNIP1 27% TNFAIP3 interacting protein 1
TEBP 27% unactive progesterone receptor, 23 kD
TAX1BP3 27% Tax1 (human T-cell leukemia virus type I) binding protein 3
TANK 27% TRAF family member-associated NFKB activator
SYPL 27% synaptophysin-like protein
SUPT6H 27% suppressor of Ty 6 homolog (S. cerevisiae)BMC Research Notes 2008, 1:60 http://www.biomedcentral.com/1756-0500/1/60
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SUPT5H 27% suppressor of Ty 5 homolog (S. cerevisiae)
SUCLG1 27% succinate-CoA ligase, GDP-forming, alpha subunit
SRI 27% sorcin
SON 27% SON DNA binding protein
SNRPD3 27% small nuclear ribonucleoprotein D3 polypeptide 18 kDa
SNAP23 27% synaptosomal-associated protein, 23 kDa
SMAP 27% small acidic protein
S100A11 27% S100 calcium binding protein A11 (calgizzarin)
RW1 27% RW1 protei
RSN 27% restin (Reed-Steinberg cell-expressed intermediate filament-associated protein)
RPL36AL 27% ribosomal protein L36a-like
RPA3 27% replication protein A3, 14 kDa
RNF4 27% ring finger protein 4
RBL2 27% retinoblastoma-like 2 (p130)
RBBP4 27% retinoblastoma binding protein 4
RARS 27% arginyl-tRNA synthetase
RANBP2 27% RAN binding protein 2
RAE1 27% RAE1 RNA export 1 homolog (S. pombe)
RAB1A 27% RAB1A, member RAS oncogene family
PXMP3 27% peroxisomal membrane protein 3, 35 kDa (Zellweger syndrome)
PTPN12 27% protein tyrosine phosphatase, non-receptor type 12
PTMA 27% prothymosin, alpha (gene sequence 28)
PSMA5 27% proteasome (prosome, macropain) subunit, alpha type, 5
PSMA4 27% proteasome (prosome, macropain) subunit, alpha type, 4
PRKDC 27% protein kinase, DNA-activated, catalytic polypeptide
PML 27% promyelocytic leukemia
PHKB 27% phosphorylase kinase, beta
NOLC1 27% nucleolar and coiled-body phosphoprotein
MUC2 27% mucin 2, intestinal/tracheal
MPI 27% mannose phosphate isomerase
MGAT1 27% mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase
MCP 27% membrane cofactor protein (CD46, trophoblast-lymphocyte cross-reactive antigen)
MARK3 27% MAP/microtubule affinity-regulating kinase 3
MARK2 27% MAP/microtubule affinity-regulating kinase 2
MARCKS 27% myristoylated alanine-rich protein kinase C substrate
MAP2K3 27% mitogen-activated protein kinase kinase 3
LIMK2 27% LIM domain kinase 2
LEREPO4 27% likely ortholog of mouse immediate early response, erythropoietin 4
KPNA2 27% karyopherin alpha 2 (RAG cohort 1, importin alpha 1)
KIAA0092 27% translokin
IL13RA1 27% interleukin 13 receptor, alpha 1
HSPE1 27% heat shock 10 kDa protein 1 (chaperonin 10)
HNRPA0 27% heterogeneous nuclear ribonucleoprotein A0
HMGN3 27% high mobility group nucleosomal binding domain 3
HLA-A 27% major histocompatibility complex, class I, A
HIF1A 27% hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)
HAT1 27% histone acetyltransferase 1
HADHA 27% hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A
thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), alpha subunit
GTF3C2 27% general transcription factor IIIC, polypeptide 2, beta 110 kDa
GRSF1 27% G-rich RNA sequence binding factor 1
GA17 27% dendritic cell protein
G3BP 27% Ras-GTPase-activating protein SH3-domain-binding protein
FUBP3 27% far upstream element (FUSE) binding protein 3
FMR1 27% fragile × mental retardation 1
FKBP1A 27% FK506 binding protein 1A, 12 kDa
FDFT1 27% farnesyl-diphosphate farnesyltransferase 1
FAM3C 27% family with sequence similarity 3, member C
EWSR1 27% Ewing sarcoma breakpoint region 1
EPS8 27% epidermal growth factor receptor pathway substrate 8
EIF3S9 27% eukaryotic translation initiation factor 3, subunit 9 eta, 116 kDa
EFNA1 27% ephrin-A1
DYRK1A 27% dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A
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DLG1 27% DLG1
DDOST 27% dolichyl-diphosphooligosaccharide-protein glycosyltransferase
DCTN6 27% dynactin 6
DBI 27% diazepam binding inhibitor (GABA receptor modulator, acyl-Coenzyme A binding)
DAZAP2 27% DAZ associated protein 2
DAG1 27% dystroglycan 1 (dystrophin-associated glycoprotein 1)
CUL4A 27% cullin 4A
CSPG6 27% chondroitin sulfate proteoglycan 6 (bamacan)
COG2 27% component of oligomeric golgi complex 2
CEBPD 27% CCAAT/enhancer binding protein (C/EBP), delta
CDC34 27% cell division cycle 34
CD9 27% CD9 antigen (p24)
CCT6A 27% chaperonin containing TCP1, subunit 6A (zeta 1)
CBX3 27% chromobox homolog 3 (HP1 gamma homolog, Drosophila)
CARS 27% cysteinyl-tRNA synthetase
C1D 27% nuclear DNA-binding protein
C14orf32 27% chromosome 14 open reading frame 32
BUB3 27% BUB3 budding uninhibited by benzimidazoles 3 homolog (yeast)
BSG 27% basigin (OK blood group)
BLOC1S1 27% biogenesis of lysosome-related organelles complex-1, subunit 1
BIRC2 27% baculoviral IAP repeat-containing 2
ARMC2 27% armadillo repeat containing 2
ANP32A 27% acidic (leucine-rich) nuclear phosphoprotein 32 family, member A
Oncomine meta-analysis of SUMO1 co-expressed genes at a cutoff of 27% overlap (4 studies).
Table 1: Oncomine meta-analysis of SUMO1 co-expressed genes (Continued)
nique has a high false-negative rate meaning that while
the co-expressed genes we see are significant we will never
get full coverage of every co-expressed gene as the strin-
gency level of analysis is high.
SUMO1 was also seen to be involved in cell death path-
ways. In 67% (10 out of 15) of the studies analyzed
SUMO1 was co-expressed with the defender against cell
death (DAD1) gene. This was the highest co-expression
with SUMO1 in the meta-analysis. As the name suggests
DAD1 is anti-apoptotic and can be upregulated in cancer
[13,14]. Other SUMO1 co-expressed genes involved in
cell death pathways include RELA, FADD, BCL2A1, BAK1,
TNFRSF1A. The high co-expression with DAD1 is a novel
finding and may prove important to SUMO1 pathways.
DEK  oncogene was the next highest co-expressed gene
(53%) with SUMO1. The DEK protein is important for
chromatin structure, and may also play a role in cell death
pathways by inhibiting apoptosis [15-17].
While co-expression meta-analysis data has previously
been shown to have a high correlation with known path-
ways in other studies [2,3], prudence should still be used
when interpreting novel findings until they can be proven
in a separate experimental system. For this reason the
meta-analysis list is presented here only as a predictive
data-driven hypothesis. The next step is experimental
analysis of DEK and DAD1 proteins to assess whether they
are targets of SUMO1 conjugation, protein-complex part-
ners of SUMO1, or act upstream or downstream of
SUMO1.
In summary, it is interesting that both of the highest co-
expressed genes of SUMO1 are anti-apoptotic, and it is
tempting to speculate that this may be an important path-
way of SUMO1 regulation.
Conclusion
Using co-expression meta-analysis from the Oncomine
database SUMO1 co-expressed with many gene products,
some which are already known to be in SUMO1 path-
ways. Novel predicted pathway partners include the DEK
oncogene and DAD1, both of which co-expressed in over
half of all studies analyzed. However, in what regard they
take part in SUMO1 pathways remains to be further inves-
tigated.
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